Cantor defends Sucampo after Maxim downgrade

Cantor's Irina Rivkind is out defending Sucampo Pharmaceuticals (SCMP -2.4%) after a downgrade from Maxim sent the shares lower.

Maxim cited lower priced Linzess (FRX, IRWD) as evidence of a "renewed competitive threat" to Amitiza.

Rivkind says after checking with management, she is confident that "Ironwood has not taken a recent price decrease to compete with SCMP."

"The competitor downgrade [is] misinformed, and an overreaction," in Rivkind's view.

Buy rating reiterated.

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs